#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Breast angiosarcoma Corneal neovascularisation Mitochondrial encephalomyopathy Piriformis syndrome Chemical burn Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Fusarium infection Fontan procedure Dupuytren's contracture Bronchiectasis Cervix carcinoma recurrent Myotonia Palmar-plantar erythrodysaesthesia syndrome Still's disease Squamous cell carcinoma of the vulva More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma stage IV IgA nephropathy – Basic Information Sarcoidosis – Trials in Disease Propionic acidaemia – Basic Information Fabry’s disease – Diagnostics Biotinidase deficiency – Trials in Disease Nephrotic syndrome – Diagnostics Soft tissue sarcoma – Basic Information Soft tissue sarcoma – Treatment Haemophilia A with anti factor VIII – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Auto4 A24110He Fenebrutinib Dcc-3116 Quercus Robur Pollen Extract Deflazacort Dronedarone Imiglucerase Ulipristal Acetate CANNABINOL Domperidone Rupatadine Palmidrol Amantadine Hemisulfate Naproxen Sodium Nazartinib Ontasameran GSK4524101A Ropivacaine Hydrochloride Magnesium Chloride Hexahydrate More therapies…

    Learn about Your Condition

    Neonatal asphyxia Intestinal infarction Renal transplant Squamous cell carcinoma Keratosis follicular Metastases to peritoneum Colorectal cancer Arteriovenous malformation Biliary adenoma Carotid arteriosclerosis Sickle cell disease Glioblastoma Embolism KBG syndrome Haemoglobinuria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of RVT-3101 for Treating Moderate to Severe Crohn’s Disease in Patients

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Pf-06480605
    • Ro7790121
    Belgium Bulgaria Czechia France Germany Hungary +5

  • Study on the Safety and Effects of Favezelimab and Pembrolizumab for Patients with Blood Cancers

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Haematological malignancy
    Investigated Drugs:
    • Favezelimab
    • Pembrolizumab
    Germany Greece Hungary Italy

  • Study of BMS-986449 and Nivolumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant mast cell neoplasm
    Investigated Drugs:
    • Bms-986449-03
    • Nivolumab
    Belgium France Italy The Netherlands Spain

  • Study of Pembrolizumab with Chemotherapy for Patients with Resectable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Pembrolizumab
    Belgium Estonia France Germany Ireland Italy +5

  • Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Apalutamide
    • Bicalutamide
    • Other Hormone Antagonists And Related Agents
    Belgium Czechia France Germany Italy Poland +3

  • Study of Futibatinib for Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Futibatinib
    Italy Poland Portugal Spain

  • Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Diphenhydramine
    • Forimtamig
    • Carfilzomib
    Denmark France Germany Italy Spain

  • Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Leiomyosarcoma metastatic
    Investigated Drugs:
    • Ondansetron Hydrochloride Dihydrate
    • Lurbinectedin
    • Filgrastim
    Austria Belgium France Germany Italy The Netherlands +3

  • Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Upadacitinib
    Austria Belgium Croatia Czechia Denmark France +13

  • Study of Tislelizumab, Surzebiclimab, and LBL-007 for Patients with Recurrent or Metastatic Head and Neck Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Lbl-007
    • Surzebiclimab
    • Tislelizumab
    France Italy Spain
Previous Page
1 … 58 59 60 61 62 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!